(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 37.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Vir Biotechnology's revenue in 2025 is $19,000,000.On average, 4 Wall Street analysts forecast VIR's revenue for 2025 to be $2,096,526,701, with the lowest VIR revenue forecast at $652,907,202, and the highest VIR revenue forecast at $5,139,907,762. On average, 4 Wall Street analysts forecast VIR's revenue for 2026 to be $1,990,255,635, with the lowest VIR revenue forecast at $652,907,202, and the highest VIR revenue forecast at $4,118,872,031.
In 2027, VIR is forecast to generate $7,843,221,412 in revenue, with the lowest revenue forecast at $675,133,830 and the highest revenue forecast at $21,657,070,813.